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phase 3 clinical trials to result in signiﬁcant pain relief in OA, with the
magnitude of the pain relief being greater than what is observed with
NSAIDs in the same studies. Importantly, this approach has also been
shown to be effective in low back pain and is being investigated in
neuropathic pain models. Currently, the further development of this
class of drugs is on hold pending a more complete understanding of
their safety proﬁle. Centrally acting compounds, speciﬁcally serotonin-
norepinephrine reuptake inhibitors (SNRIs) have also been shown to
provide pain modiﬁcation in musculoskeletal pain conditions (OA, low
back pain), adding to the armamentarium available for the manage-
ment of these conditions. Novel topical agents as well as different
formulations of existing opioids are also being investigated at this time.
In terms of disease modiﬁcation, recent trials have examined the effects
of oral calcitonin on progression of structural disease as well as evalu-
ating inhibition of the inducible nitric oxide synthase pathway, believed
to be responsible for inﬂammatory and catabolic pathways in cartilage
leading to OA.
Conclusions: Inhibition of both peripheral and central pain pathways
has been shown to be effective at reducing pain and improving function
in people with OA. Further studies are needed to deﬁne the safety
proﬁle of therapy directed at inhibition of NGF. Disease modiﬁcation
remains a challenging goal, but a better understanding of the mecha-
nism of cartilage damage has allowed new agents to be considered for
study in this condition.
I-8
NOVEL AND TARGETED THERAPIES FOR OA
N. Lane. Univ. of California at Davis, Ctr. for Musculoskeletal and Aging
Res., Sacramento, CA
The treatment of osteoarthritis (OA) and its associated pain remains an
unmet medical need, and our limited ability to effectively treat the
disease is due to deﬁcits in our understanding of both the pathophys-
iology of OA and the factors associated with the progression of the
disease. However, a number of novel and targeted treatments for
painful knee OA have been studied and demonstrate efﬁcacy, and
a selected number will be discussed.
Novel therapies. Recent studies of monoclonal antibodies that inhibit
nerve growth factor have been studied in moderate to severe knee
OA:tanezumab, injected every 8 weeks was found to reduce walking
knee pain nearly 50% more than placebo-treated subjects, and subjects
reported signiﬁcant improvement in pain and function over the 16
week study. A selective serotonin reuptake inhibitor approved for the
treatment of chronic painful conditions including ﬁbromyalgia
(duloxetine (60-120 mg/d)) was evaluated in an RCT of 250 subjects
with moderate knee OA for 13 weeks, and compared to a placebo
group it reduced knee pain by more than 50% and also improved
function. Exercise regimens have also had some success in the treat-
ment of pain from knee OA. Tai chi twice a week for 12 weeks was
evaluated in an RCT. WOMAC pain, WOMAC physical function and
physician VAS improved by 70% in the tai chi group from baseline, and
all outcome differences were p<0.05 compared to the attention-only
control group.
Targeted therapies. Since knee OA is frequently a localized disease, the
use of targeted local treatments has been studied. Intra-articular
injections of viscosupplementation have been used for the treatment of
knee pain. A comparator study of Hylan GF-20 (3 weekly injections) and
Sodium Hyaluronate (5 weekly injections) found signiﬁcant reduction
in knee pain by VAS, however it was sustained for 12 months in the
Hylan GF-20 group, and only for 6 months with Sodium Hyaluronate.
Interestingly, an RCTof Hylan GF-20 vs. placebowith treatments every 6
months for 24 months demonstrated a signiﬁcant beneﬁcial effect on
knee cartilage preservation measured by both cartilage volume and
cartilage defects. Onabotulinumtoxin A directly blocks peripheral
sensation through suppression of inﬂammatory neuropeptides arising
from sensory neurons, and can block both localized and central pain. An
RCT of onabotulinumtoxin A (100 U, 200 U) vs. methylprednisolone
40 mg found signiﬁcant reduction in VAS pain from baseline which was
sustained longer in the onabotulinumtoxin A group. Physical joint
distraction has been performed in a small study, and the reduction in
WOMAC pain subscale during the treatment was further improved and
maintained through 10 months post-distraction. Transplantation of
mesenchymal stem cells is also being evaluated but clinical studies
currently are lacking.I-9
PERIFIBRILLAR PROTEINS IN THE CARTILAGE EXTRACELLULAR
MATRIX
R. Wagener. Ctr. for Biochemistry, Univ. of Cologne, Cologne, Germany
To fulﬁl its function as a ﬂexible but simultaneously strongly supportive
tissue, a proper cartilage is dependent on the scaffold that is formed by
a network of large collagen ﬁbrils that are embedded in a proteoglycan
gel. However, to form, organise and maintain these macromolecular
networks accessory proteins are needed. A subset of such proteins is
found close to or at the surface of the collagen ﬁbrils, thereby creating
a “periﬁbrillar”matrix of a deﬁned composition. The periﬁbrillar matrix
may be of relevance for the regulation of collagen ﬁbrillogenesis and for
interactions between large collagen ﬁbrils, for their interactionwith the
proteoglycan gel and for interactions between large ﬁbrils and the
collagen VI containing microﬁbrils. Examples for pericellular proteins
are non-ﬁbril forming collagenmolecules of the FACIT type, small leucin
rich repeat proteoglycans as well as other abundant noncollagenous
proteins, like COMP (cartilage oligomeric matrix protein) and matrilins.
These all participate in the formation of ﬁbrillar or ﬁlamentous struc-
tures and mediate interactions between collagen ﬁbrils and other
matrix constituents. Interestingly, whereas the ablation of the Col2a1 or
the Acan genes in mice is perinatal lethal, the ablation of genes coding
for periﬁbrillar proteins leads to much milder phenotypes or shows
disturbances only detectable at the molecular level, perhaps indicating
redundancy due to the multiplicity of interconnections between these
proteins. In contrast, more severe phenotypes are observed when
mutations in genes coding for periﬁbrillar proteins affect protein
folding in the secretory pathway which leads to ER stress due to an
unfolded protein response. The lack of obvious phenotypes in single
knockouts of periﬁbrillar proteins can be partially overcome by the
generation of multiple knockouts, but even these mice often show only
mild phenotypes. Consequently, our current knowledge of the in vivo
function of pericellular proteins is predominantly based on in vitro
studies. We recently found that zebraﬁsh, a less complex vertebrate
animal model organism, is an alternative to study pericellular protein
function in vivo. When investigating the function of the prototypic
periﬁbrillar protein matrilin-1 in zebraﬁsh larvae we found that in
contrast to in mouse the knockdown of matrilin-1 by morpholino
antisense oligonucleotides has drastic consequences for cartilage
development and a proper cartilage is not formed. Instead, a mesen-
chymal tissue develops that lacks the major cartilage components
collagen II and aggrecan. Moreover, in severely affected larvae the cells
display “chondroptosis”, a variant of apoptosis in chondrocytes. Taken
together it is likely that the loss of matrilin-1 has an effect already
within the secretory pathway, where matrilin-1 may facilitate the
secretion of bulk extracellular matrix components. Nevertheless, it
remains obscure why this obvious phenotype occurs in zebraﬁsh and
not in mouse.
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OA BIOMARKERS: HOW WILL WE RECOGNIZE THE REAL MCCOY?
G. Moxley. Virginia Commonwealth Univ., Richmond, VA
This presentation aims to provide a conceptual overview for the OA
biomarkers session. A biomarker may be deﬁned thus: “a characteristic
[distinctive mark, trait, or feature] that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic
processes, or pharmacological responses to a therapeutic intervention.”
Implicit is that the biomarker lies along a pathogenetic pathway leading
to a clinical endpoint (how the patient feels, functions, or survives). A
surrogate marker may be thought of as a biomarker that approximates
a clinical endpoint and is expected to predict a clinical beneﬁt or harm.
One sees at once that current OA interventions are neither preventive
nor curative, and signiﬁcant obstacles block development. We can
expect that -omic and experimental biology investigations will outline
OA pathogenetic pathways, and so can anticipate ﬁnding biomarkers
among such pathways. Biomarkers could detect early OA, help under-
standing of pathogenesis, lead to prediction of outcome and alter
management, and aid drug development. In anticipation, a preliminary
classiﬁcation for OA biomarkers has been developed; its acronym BIPED
refers to Burden of disease, Investigative, Prognostic, Efﬁcacy of inter-
vention, and Diagnostic, with the later addition of Safety. To identify
useful biomarkers, we require clinical endpoints that deﬁne how an OA
patient feels and functions. The recent description of virtual joint
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structural damage representing need for replacement hip/knee
arthroplasty) is a step forward, but analogous measures are needed for
other OA-affected joint regions like spine and hand.
The process of deﬁning a biomarker's usefulness may be summarized
conceptually in laboratory assay performance (analytical validation),
reviewing correlation with clinical outcomes or therapeutic response
(qualiﬁcation), and deﬁning a real-life context inwhich the biomarker is
useful (utilization). For example, LDL cholesterol has high analytical
validity and extensive evidence supporting its role in atherogenesis, is
utilized in risk prediction for cardiovascular disease, and even can be
used as a surrogate endpoint for cardiovascular events with statin
interventions. Imagine then a future OA biomarker that is analytically
valid when measured in blood or urine (or even synovial ﬂuid), has
extensive relationship to cartilage repair or regeneration or pain, and
predicts risk for later development of virtual joint replacement. Imagine
as well that a future intervention will change this biomarker's levels in
a manner that correlates with and captures reduced risk for virtual joint
replacement. That is where we want to be. Yet howwill we know when
we get there?
 We ask, “Can we measure it well enough?” When an OA biomarker
can be reliably measured, we'll see publications showing little
extraneous variation and agreement among various assays and
laboratories with deﬁned international standards.
 We ask, “Does it connect rationally to the OA features we see?”
When an OA biomarker is connected reproducibly to disease
outcome and possibly intervention, we'll see abundant evidence
that a biomarker lies along a known pathogenetic pathway within
a deﬁned biological model (such as by Bradford Hill criteria),
correlates with symptoms or function or structural alteration, and
maybe captures response to an intervention.
 We ask, “How should it be used?” When an OA biomarker applies
to a speciﬁc proposed use, we'll see epidemiological studies
showing an important and clinically useful context for the
biomarker use, such as in prevention, diagnosis, treatment, or
mitigation.
Thus, with the fruits of genomic approaches to ﬁnd genes that lie along
OA pathogenetic pathways and of experimental biology studies to
deﬁne how variants confer risk, we can expect to identify biomarker
candidates to be characterized as potential OA biomarkers.
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THE RELEVANCE OF THE HUPO HUMAN PROTEOME PROJECT FOR
PROTEOMICS STUDIES OF OSTEOARTHRITIS
G.S. Omenn. Univ. of Michigan, Ann Arbor, MI
Purpose: To identify and characterize at least one protein from each of
the 20,300 human protein-coding genes. See Legrain et al., Mol. Cell
Proteomics (2011). To facilitate disease-related biomarker development.
Methods: Global collaborative Human Proteome Project (HPP), orga-
nized by the Human Proteome Organization (HUPO). Use of Proteo-
meXchange, linking data repositories EBI-PRIDE and neXtprot, ﬁle
sharing system Tranche, mass spectrometry-based Peptide Atlas and
SRM Atlas, and Ab-based Human Protein Atlas, to share data, reanalyze
mass spectrometry ﬁndings with a rigorous, standardized protocol, and
lay the foundation for protein biomarkers of health and disease.
Results: The Human Proteome Project was announced at the HUPO
World Congress in Sydney, Australia, in September 2010 and launched at
the HUPO World Congress in Geneva, Switzerland, in September 2011.
The HPP draws upon resource pillars for mass spectrometry, protein
capture, and knowledge base. There is some degree of evidence at the
protein level for about 13,000 of the 20,300 proteins. The HPP has two
large collaborative components: the chromosome-centric C-HPP, with so
far 16 national or international research teams characterizing the
proteins coded by genes on one chromosome each; and the biology and
disease-driven B/D-HPP, which has embraced the pre-existing organ-
based and bioﬂuid-based proteome projects of the past decade under the
aegis of HUPO. For example, the chromosome 17 team is annotating the
1182 proteins coded by genes on this chromosome (based on Ensembl,
SwissProt, and neXtprot), with a disease focus on breast cancer, reﬂecting
the breast cancer-associated Chr 17 genes ERBB2 (Her2), BRCA1, p53, and
GRB7. We are determining the concordance of protein identiﬁcations by
immunohistochemistry and by mass spectrometry and the tissueexpression patterns for the canonical proteins and for splice variants and
various types of post-translational modiﬁcations. Information about the
HPP is available at http://thehpp.org.
Conclusions: The combined chromosome-centric and biology and
disease-driven Human Proteome Project efforts are becoming well-
organized. The HPP will add greatly to our conﬁdent identiﬁcation of
human proteins currently not yet identiﬁed or mapped for tissue and
subcellular expression. The HPP provides a foundation for interpreting
results of proteomic biomarker studies of osteoarthritis and integrating
proteomics data with other omics platforms to relate genotype to
phenotype (Figure 1).
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SURGICAL MANAGEMENT OF OSTEOARTHRITIS: OPTIONS AND
OUTCOMES
J.N. Katz. Brigham and Women's Hosp., Boston, MA
Purpose: To review the options and outcomes of surgical management
of osteoarthritis of the knee and hip.
Methods: Review of pertinent peer reviewed literature.
Results: Arthroscopic lavage and debridement are no more efﬁcacious
than sham surgery or physical therapy in the management of osteoar-
thritis of the knee. The efﬁcacy of arthroscopic partial meniscectomy in
the management of meniscal tear in the setting of knee ostearthritis is
uncertain and requires further study. There has been little rigorous
comparison of osteotomy or unicompartmental knee arthroplasty with
nonoperative treatments for knee OA. Total joint arthroplasty is an
effective and cost effective intervention for advanced knee or hip
osteoarthritis. The utilization of total knee arthroplasty has expanded
considerably into younger and older populations, particularly patients
<65 years old. The outcomes of TKA in this population requires careful
study. New surgical approaches, devices and biomaterials are intro-
duced routinely in an effort to improve outcomes of total joint arth-
plasty. These innovations must be scrutinized carefully before
widespread adoption in order to ensure that they improve upon the
excellent short and long term outcomes achieved with existing
technology.
Conclusions:Whilecontinued research isneededurgently to optimzeuse
of these costly interventions, a growing body of evidence permits judi-
cious use of surgical interventions for osteoarthritis of the hip and knee.
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TECHNICAL DEVELOPMENTS IN GENETIC MODIFIED ANIMAL MODEL
P.M. van der Kraan. Radboud Univ., Med. Ctr., Nijmegen, Netherlands
Animal models are until now irreplaceable tools of osteoarthritis
research. Studies can make use of either spontaneous occurring oste-
oarthritis or of induced models to study the disease process. However,
the role of speciﬁc genes and proteins in osteoarthritis has made a big
step forward after the generation of transgenic animal models, mainly
in the mouse. The generation of transgenic animal models has shown
a vast development in the years since the ﬁrst transgenic mouse was
created bymicro-injection and random integration of DNA. The creation
of knock out mice, the use of tissue speciﬁc promoters, ﬂoxed mice, and
the introduction of inducible expression systems has advanced the
usability of these transgenic mice in OA research worldwide. This
workshop will focus on the latest developments in murine transgenics
and illustrate the contribution of these models to our understanding of
the OA disease process.
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BIOLOGICAL SURGICAL REPAIR
A.H. Gomoll. Brigham and Women's Hosp., Boston, MA
Articular cartilage defects are common, being encountered inmore than
half of all knee arthroscopies. While not all defects are symptomatic,
those that are can cause disability comparable to that seen in patients
awaiting knee replacement for advanced osteoarthritis. Knee replace-
ment provides good pain relief with relatively high patient satisfaction
over 70%, and 10 year survival rates of 80% to 90%. However, the
majority of these studies were conducted in older patients, ranging in
age from the late 60s to early 80s. Younger patients are less satisﬁed
with the outcome and also demonstrate higher implant failure rates. It
therefore appears reasonable to attempt delaying arthroplasty as long
as possible, especially in young patients.
